Callahan Advisors buys $1,189,013 stake in Natus Medical Inc (BABY)

Natus Medical Inc (BABY) : Callahan Advisors scooped up 6,835 additional shares in Natus Medical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 29,250 shares of Natus Medical Inc which is valued at $1,189,013.Natus Medical Inc makes up approximately 0.30% of Callahan Advisors’s portfolio.

Other Hedge Funds, Including , Legal General Group Plc boosted its stake in BABY in the latest quarter, The investment management firm added 22,100 additional shares and now holds a total of 31,107 shares of Natus Medical Inc which is valued at $1,266,055.Eagle Asset Management Inc reduced its stake in BABY by selling 263,833 shares or 9.15% in the most recent quarter. The Hedge Fund company now holds 2,618,330 shares of BABY which is valued at $106,566,031. Natus Medical Inc makes up approx 0.73% of Eagle Asset Management Inc’s portfolio.Creative Planning boosted its stake in BABY in the latest quarter, The investment management firm added 314 additional shares and now holds a total of 1,324 shares of Natus Medical Inc which is valued at $53,887. Eqis Capital Management added BABY to its portfolio by purchasing 7,404 company shares during the most recent quarter which is valued at $299,788. Natus Medical Inc makes up approx 0.02% of Eqis Capital Management’s portfolio.

Natus Medical Inc closed down -0.15 points or -0.37% at $40.65 with 1,84,496 shares getting traded on Friday. Post opening the session at $41.05, the shares hit an intraday low of $40.25 and an intraday high of $41.05 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Natus Medical Inc reported $0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.36. The company had revenue of $96.00 million for the quarter, compared to analysts expectations of $92.71 million. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS.

Many Wall Street Analysts have commented on Natus Medical Inc. The Benchmark Company Initiated Natus Medical Inc on Oct 4, 2016 to “Buy”, Price Target of the shares are set at $55.Natus Medical Inc was Upgraded by Raymond James to ” Outperform” on Sep 13, 2016.

Natus Medical Incorporated (Natus) is a provider of newborn care and neurology healthcare products and services used for the screening diagnosis detection treatment monitoring and tracking of common medical ailments in newborn care hearing impairment neurological dysfunction epilepsy sleep disorders and balance and mobility disorders. The Company offers two product families: Neurology which includes products and services for diagnostic electroencephalography and long term monitoring intensive care unit monitoring electromyography sleep analysis intra-operative monitoring and diagnostic and monitoring transcranial doppler ultrasound technology; and Newborn Care which includes products and services for newborn care including hearing screening brain injury thermoregulation jaundice management and various disposable products as well as products for diagnostic hearing assessment for children through adult populations and others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Natus Medical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Natus Medical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.